These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 25996664)

  • 1. Novel reversible selective inhibitor of nuclear export shows that CRM1 is a target in colorectal cancer cells.
    Niu M; Chong Y; Han Y; Liu X
    Cancer Biol Ther; 2015; 16(7):1110-8. PubMed ID: 25996664
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel reversible selective inhibitor of CRM1 for targeted therapy in ovarian cancer.
    Liu X; Chong Y; Liu H; Han Y; Niu M
    J Ovarian Res; 2015 Jun; 8():35. PubMed ID: 26055813
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CRM1/XPO1 is associated with clinical outcome in glioma and represents a therapeutic target by perturbing multiple core pathways.
    Liu X; Chong Y; Tu Y; Liu N; Yue C; Qi Z; Liu H; Yao Y; Liu H; Gao S; Niu M; Yu R
    J Hematol Oncol; 2016 Oct; 9(1):108. PubMed ID: 27733172
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CBS9106 is a novel reversible oral CRM1 inhibitor with CRM1 degrading activity.
    Sakakibara K; Saito N; Sato T; Suzuki A; Hasegawa Y; Friedman JM; Kufe DW; Vonhoff DD; Iwami T; Kawabe T
    Blood; 2011 Oct; 118(14):3922-31. PubMed ID: 21841164
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CRM1 inhibitor S109 suppresses cell proliferation and induces cell cycle arrest in renal cancer cells.
    Liu X; Chong Y; Liu H; Han Y; Niu M
    Korean J Physiol Pharmacol; 2016 Mar; 20(2):161-8. PubMed ID: 26937212
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of CRM1-dependent nuclear export sensitizes malignant cells to cytotoxic and targeted agents.
    Turner JG; Dawson J; Cubitt CL; Baz R; Sullivan DM
    Semin Cancer Biol; 2014 Aug; 27():62-73. PubMed ID: 24631834
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ratjadone and leptomycin B block CRM1-dependent nuclear export by identical mechanisms.
    Meissner T; Krause E; Vinkemeier U
    FEBS Lett; 2004 Oct; 576(1-2):27-30. PubMed ID: 15474004
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CBS9106-induced CRM1 degradation is mediated by cullin ring ligase activity and the neddylation pathway.
    Saito N; Sakakibara K; Sato T; Friedman JM; Kufe DW; VonHoff DD; Kawabe T
    Mol Cancer Ther; 2014 Dec; 13(12):3013-23. PubMed ID: 25253782
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antileukemic activity of nuclear export inhibitors that spare normal hematopoietic cells.
    Etchin J; Sun Q; Kentsis A; Farmer A; Zhang ZC; Sanda T; Mansour MR; Barcelo C; McCauley D; Kauffman M; Shacham S; Christie AL; Kung AL; Rodig SJ; Chook YM; Look AT
    Leukemia; 2013 Jan; 27(1):66-74. PubMed ID: 22847027
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structure-Guided Design of the First Noncovalent Small-Molecule Inhibitor of CRM1.
    Lei Y; An Q; Shen XF; Sui M; Li C; Jia D; Luo Y; Sun Q
    J Med Chem; 2021 May; 64(10):6596-6607. PubMed ID: 33974430
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Leptomycin B alters the subcellular distribution of CRM1 (Exportin 1).
    Rahmani K; Dean DA
    Biochem Biophys Res Commun; 2017 Jun; 488(2):253-258. PubMed ID: 28412356
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CRM1/Ran-mediated nuclear export of p27(Kip1) involves a nuclear export signal and links p27 export and proteolysis.
    Connor MK; Kotchetkov R; Cariou S; Resch A; Lupetti R; Beniston RG; Melchior F; Hengst L; Slingerland JM
    Mol Biol Cell; 2003 Jan; 14(1):201-13. PubMed ID: 12529437
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preclinical activity of a novel CRM1 inhibitor in acute myeloid leukemia.
    Ranganathan P; Yu X; Na C; Santhanam R; Shacham S; Kauffman M; Walker A; Klisovic R; Blum W; Caligiuri M; Croce CM; Marcucci G; Garzon R
    Blood; 2012 Aug; 120(9):1765-73. PubMed ID: 22677130
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nuclear export of proteins and drug resistance in cancer.
    Turner JG; Dawson J; Sullivan DM
    Biochem Pharmacol; 2012 Apr; 83(8):1021-32. PubMed ID: 22209898
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-tumor activity of selective inhibitors of XPO1/CRM1-mediated nuclear export in diffuse malignant peritoneal mesothelioma: the role of survivin.
    De Cesare M; Cominetti D; Doldi V; Lopergolo A; Deraco M; Gandellini P; Friedlander S; Landesman Y; Kauffman MG; Shacham S; Pennati M; Zaffaroni N
    Oncotarget; 2015 May; 6(15):13119-32. PubMed ID: 25948791
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of CRM1-mediated nucleocytoplasmic transport: triggering human melanoma cell apoptosis by perturbing multiple cellular pathways.
    Pathria G; Wagner C; Wagner SN
    J Invest Dermatol; 2012 Dec; 132(12):2780-90. PubMed ID: 22832492
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nuclear export inhibition through covalent conjugation and hydrolysis of Leptomycin B by CRM1.
    Sun Q; Carrasco YP; Hu Y; Guo X; Mirzaei H; Macmillan J; Chook YM
    Proc Natl Acad Sci U S A; 2013 Jan; 110(4):1303-8. PubMed ID: 23297231
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CRM1 Promotes Capsid Disassembly and Nuclear Envelope Translocation of Adenovirus Independently of Its Export Function.
    Lagadec F; Carlon-Andres I; Ragues J; Port S; Wodrich H; Kehlenbach RH
    J Virol; 2022 Feb; 96(3):e0127321. PubMed ID: 34757845
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CRM1-dependent, but not ARE-mediated, nuclear export of IFN-alpha1 mRNA.
    Kimura T; Hashimoto I; Nagase T; Fujisawa J
    J Cell Sci; 2004 May; 117(Pt 11):2259-70. PubMed ID: 15126627
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Crm1 is a mitotic effector of Ran-GTP in somatic cells.
    Arnaoutov A; Azuma Y; Ribbeck K; Joseph J; Boyarchuk Y; Karpova T; McNally J; Dasso M
    Nat Cell Biol; 2005 Jun; 7(6):626-32. PubMed ID: 15908946
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.